<?xml version="1.0" encoding="utf-8" ?>
<INTERACTIONS>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>101-BRADYCARIA-INDUCING-DRUGS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="BRADYCARIA INDUCING DRUGS" code="C0N0S0" /></DRUG1>
<DRUG2>
<CLASS name="OTHER BRADYCARIA INDUCING DRUGS" code="C0N0S0" /></DRUG2>
<DESCRIPTION>Risk of excessive bradycardia (addition of the effects)</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>101-BRADYCARIA-INDUCING-DRUGS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="BRADYCARIA INDUCING DRUGS" code="C0N0S0" /></DRUG1>
<DRUG2>
<DRUG name="FINGOLIMOD" rxcui="1012892">
<ATC code="L04AA27" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the bradycardia inducing effects which can have fatal consequences. The beta-blocking agents are even more at risk since they inhibit the adrenergic compensation mechanisms</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>Clinical monitoring and sustained EKG during the 24 hours following the first dose.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>101-BRADYCARIA-INDUCING-DRUGS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="BRADYCARIA INDUCING DRUGS" code="C0N0S0" /></DRUG1>
<DRUG2>
<CLASS name="SUBSTANCES THAT TEND TO INDUCE TORSADES DE POINTES" code="C01-N05" /></DRUG2>
<DESCRIPTION>Increased risk of ventricular arrhythmias, especially of torsades de pointes</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and EKG during the administration of these together. </COMMENT>
</INTERACTION>
</INTERACTIONS>
